USMIRC news is media for plasma cell disorders, Myeloid and Lymphona news, blogs and updates #USMIRC #mmsm

Kansas City, MO
Joined November 2023
Honestly, no paper, citation, conference talk, or clinical trial could give me the feeling I have today. Kansas has finally closed the gap with the national myeloma mortality rate. After years of hard work, being part of this milestone means more to me than anything on my CV. I think about the patients we’ve cared for, the families we’ve come to know, and everyone who kept showing up and believed we could do better. I’m just grateful I got to be part of it. We did it TEAM! @KUcancercenter #mmsm #myeloma #MedEd #medtiwtter #USMIRC @USMIRCNEWS @OpenMedKate @Larvol @CancerNetwrk @oncodaily @VuMediHemOnc @US_HMC
3
4
1
59
2,747
Hematopoietic Stem Cell Transplantation for the Management of Histiocytic Sarcoma: A Case Report and Systematic Review. Transplantation Proceedings. 2026 @KUcancercenter @USMIRCNEWS @mrf_org sciencedirect.com/science/ar…
1
1
174
A pleasure to have hosted our 5th GVTP fellow, Dr. Maher Bani Essa, from Jordanian Royal Medical Services. Looking forward to supporting his efforts to develop the Transplantation & Cellular Therapy Program in Amman, Jordan. @KUcancercenter @KUMedCenter @mrf_org @USMIRCNEWS #GVTP #GlobalHealth #BMT #CellTherapy
2
2
197
Al-Ola Abdallah, MD (@KUMedCenter) discusses IMiD-based holding therapy before leukapheresis and its safety in patients with #myeloma receiving CAR T-cell therapy. 🎥 WATCH: targetedonc.com/view/al-ola-… #IMS2026 #CARTCellTherapy #Hematology #Oncology | @Abdallah81MD
1
7
1
9
1,118
84 pt with Penta-refractory, BCMA-exposed myeloma with secondary PCL: brief teclistamab, stopped for infections—still in remission 44 months off therapy! As BCMA BiTE combinations move earlier, we should study de-escalation and MRD-guided treatment discontinuation. #Myeloma #USMIRC #mmsm #MedEd #medtwitter @USMIRCNEWS @US_HMC @Larvol @OpenMedKate @oncodaily 👇👇 mdpi.com/2072-6694/17/21/356…
2
8
2
21
3,089
Shahzad M … Mushtaq MU. Impact of CD34+ graft cell dose on acute GVHD and engraftment in matched sibling donor peripheral blood stem cell transplantation with post-transplant cyclophosphamide prophylaxis: a CIBMTR analysis. Bone Marrow Transplantation. 2026 @KUcancercenter @USMIRCNEWS @mrf_org @mshahzadmd nature.com/articles/s41409-0…
3
7
230
Amin MK … Mushtaq MU. Incidence, Patterns, and Outcomes of Fungal Infections in Patients With Graft Versus Host Disease Requiring Systemic Steroids Following Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta Analysis. Transplantation Proceedings. 2026 @KUcancercenter @USMIRCNEWS @mrf_org @mshahzadmd sciencedirect.com/science/ar…
4
4
284
Shahzad M … Mushtaq MU. Impact of Early Bloodstream Infections on Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis. Transplantation and Cellular Therapy. 2026 @KUcancercenter @USMIRCNEWS @mrf_org @mshahzadmd sciencedirect.com/science/ar…
1
1
118
🧬 ICE-T Conference Series: Immune Cell Effector Therapy Join us November 7, 2026, at the University of Kansas Medical Center in Kansas City, Kansas, for a one-day conference exploring the latest advances in cellular immunotherapy. Experts from leading cancer centers will discuss CAR T-cell therapy, bispecific antibodies, toxicity management, survivorship, and emerging applications in solid tumors and autoimmune disease. Designed for physicians, APPs, pharmacists, nurses, researchers, trainees, program leaders and other professionals involved in cancer care and cellular therapy. 📅 November 7, 2026 📍 KU Medical Center | Health Education Building Register today! ow.ly/r1nb50ZTKyR
3
1
5
1,708
Congratulations @mshahzadmd and @mumairmushtaq on this amazing achievement
Proud to share we'll be presenting 60+ abstracts at #ASH26, including 7 oral presentations! A tremendous reflection of #mentorship & #collaboration across borders.Congratulations to everyone who contributed to this achievement @MoffittNews @mumairmushtaq @kashifaminMD @USMIRCNEWS
4
143
Choices, Hope and Science: Treating blood disorders How Gene Therapy and CAR T-Cell Therapy Are Changing Lives!! Another great episode of @KUcancercenter @KUHospitalNews @KCTV5
2
2
4
511
#IMS26✨ - Great to see several of our USMIRC collaborative projects presented at the International Myeloma Society Annual Meeting in Glasgow last week! Our work included real-world questions that come up frequently in clinical practice, including whether IMiD-based holding therapy prior to CAR-T impacts outcomes and the safety and efficacy of talquetamab in patients with renal insufficiency. These are exactly the kinds of questions where multi-institutional real-world data can help inform how we care for patients who may not always be well represented in clinical trials. Lots more to come! And a mandatory picture with the IMS sign! 😊 @Abdallah81MD @MansiShahMD VeenaKrishnan JordanSnyder @AtrashShebli @hiragss
2
5
1
20
1,658
What an incredible group to collaborate with through #USMIRC! Looking forward to seeing everyone on November 7 at the National ICE-T Congress! 🧬💪 @USMIRCNEWS #mmsm #myeloma
#IMS26✨ - Great to see several of our USMIRC collaborative projects presented at the International Myeloma Society Annual Meeting in Glasgow last week! Our work included real-world questions that come up frequently in clinical practice, including whether IMiD-based holding therapy prior to CAR-T impacts outcomes and the safety and efficacy of talquetamab in patients with renal insufficiency. These are exactly the kinds of questions where multi-institutional real-world data can help inform how we care for patients who may not always be well represented in clinical trials. Lots more to come! And a mandatory picture with the IMS sign! 😊 @Abdallah81MD @MansiShahMD VeenaKrishnan JordanSnyder @AtrashShebli @hiragss
2
5
587
USMIRC News retweeted
DPd or DKd in relapsed myeloma? Efficacy may be similar—but toxicity differs. Our real-world study of 399 patients: • mPFS: 15 vs 12 mo (p=0.20)
 • Grade ≥3 neutropenia: 36% vs 23%
 • CV events: 18% vs 29% Distinct toxicity profiles may guide regimen selection.
1
1
3
106
Should BCMA-directed CAR T-cell therapy be preferred before BCMA-targeted bispecific antibodies in relapsed multiple myeloma? CAR-T vs BiTE in Myeloma #mmsm #myeloma #USMIRC mdpi.com/2072-6694/18/19/314…
1/🧵 Just published in Cancers from the #USMIRC @USMIRCNEWS : CAR-T vs BiTE🔥 one of the largest multicenter real-world studies comparing BCMA-directed CAR-T therapy with bispecific antibodies in relapsed/refractory multiple myeloma. We analyzed 356 patients across 7 US academic centers. 🔬 In patients receiving their first BCMA-directed therapy (n=276): 🔹 CAR-T: 169 patients 🔹 Teclistamab: 107 patients Overall response rate was 87% with CAR-T versus 68% with teclistamab. 📊 #mmsm #myeloma #MedEd #Medtiwtter #USMIRC @US_HMC @USMIRCNEWS @Larvol @oncodaily @OpenMedKate
3
7
539
USMIRC News retweeted
Hi #MedTwitter! 👋 I’m Zara Baloch, MBBS, an ECFMG-certified IMG based in Florida, applying to #InternalMedicine for #Match2027. 🔬 Passionate about research, Heme/Onc, medical education & patient advocacy 🎙️ Director of Research & Medical Correspondent at MedNews Week 🎧 Creator & Co-host of Match Confidential Fun fact: A year ago, I never imagined I’d be hosting conferences or interviewing physicians and researchers. Through MedNews Week, I unexpectedly grew to love it, especially the opportunity to learn firsthand from leaders shaping the field. Outside medicine, curiosity describes me best. I love art, museums, nature, ancient civilizations & documentaries (almost always over fiction!). I’m happiest exploring something I haven’t seen or learned about before, from trying freediving to spending hours in a museum. And no matter what city I’m in, I somehow always find a pickleball court. 🏓 I’m also drawn to Stoic philosophy, particularly Marcus Aurelius, and enjoy incorporating lessons from The Daily Stoic into everyday life. “The impediment to action advances action. What stands in the way becomes the way.” -Marcus Aurelius Looking forward to connecting with applicants, residents, faculty & mentors this Match season! AAMC ID: 16315579 @MedNewsWeek @ProjectImg #IMG #ERAS #ECFMG #MedEd #HematologyOncology #match2027 #ERAS2027
14
13
2
226
34,344
Alhamdulillah — a wonderful day at #IMS2026 in Glasgow, reconnecting with colleagues, exchanging ideas, and learning from the global myeloma community. Grateful for the conversations, collaborations, and friendships along the way🩸 @KUcancercenter @mrf_org @USMIRCNEWS #InternationalMyelomaSociety #MultipleMyeloma #Glasgow #KUCC #WeAreNCIComprehensive
1
3
330